.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Covington
Express Scripts
Chinese Patent Office
Medtronic
Baxter
Teva
McKinsey
Farmers Insurance
Harvard Business School

Generated: September 19, 2017

Patent: ► Subscribe

Summary for Patent: ► Subscribe

Title:Method for predicting the response to treatment with an HER2-blocking agent
Abstract: The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer.
Inventor(s): Pages; Gilles (Monaco, MC)
Assignee: UNIVERSITE DE NICE SOPHIA ANTIPOLIS (Nice, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR)
Application Number:14/125,155
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe UNIVERSITE DE NICE SOPHIA ANTIPOLIS (Nice, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) Pages; Gilles (Monaco, MC) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France11 55128Jun 10, 2011
PCT Information
PCT FiledJune 07, 2012PCT Application Number:PCT/EP2012/060807
PCT Publication Date:December 13, 2012PCT Publication Number: WO2012/168370

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Canada2838767Dec 13, 2012
European Patent Office2718462Apr 16, 2014
France2976294Dec 14, 2012
Japan2014519330Aug 14, 2014
United States of America2014377252Dec 25, 2014
World Intellectual Property Organization (WIPO)2012168370Dec 13, 2012
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
Citi
Argus Health
McKesson
Covington
Deloitte
UBS
Cerilliant
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot